Across TCGA pan-cancer cohorts, FAM177B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM177B data layer compared with 24 for mass-spec protein.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher FAM177B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM177B expression acts as an unfavorable survival marker.
GBM are the cancer types where FAM177B Mutation most reproducibly stratifies survival.